Scientific News

In order to assess the usage of "unconventional treatment" for autoimmune hepatitis (AIH) in our ERN community, we would like to perform an online survey to collect the experiences with these new treatments in our patients. We define "unconventional treatment" as new agents that have not been defined as 2nd or 3rd line treatment for AIH in the past and are used more in the fields of dermatology, rheumatology or inflammatory bowel disease.  [read more]

Non-cirrhotic portal vein thrombosis is associated with one or several underlying risk factors of thrombosis in 60-70 percent of cases, including major prothrombotic risk factor (e.g. myeloproliferative neoplasms, antiphospholipid syndrome, or homozygous factor V Leiden), and transient (local causes) or mild to moderate risk factors (e.g. heterozygous G20210A factor II or G1691A factor V mutations,…).  [read more]

While alpha1-antitrypsin deficiency (AATD) - associated liver disease is still greatly understudied, several recently published studies improved our knowledge about this genetic condition caused by mutations in the SERPINA1 gene encoding for alpha-1 antitrypsin. [read more]

The results of the EU survey on the availability of age-appropriate medication for children with autoimmune liver disease (AILD) were recently published with the Journal of Hepatology. [read more]

During the ongoing SARS-CoV-2 pandemic it is of great importance to identify patients at risk of a severe course of COVID-19. [read more]

The authors previously published the results of an international collaboration of three large registries, including the R-LIVER registry of ERN RARE-LIVER, on COVID-19 in adult patients with autoimmune hepatitis. In this work, the authors report on 21 pediatric liver transplantation (LT) recipients and 16 pediatric chronic liver disease (CLD) patients with confirmed SARS-CoV-2 infection from 10 European centres.  [read more]